GB0706633D0 - Combination - Google Patents

Combination

Info

Publication number
GB0706633D0
GB0706633D0 GBGB0706633.5A GB0706633A GB0706633D0 GB 0706633 D0 GB0706633 D0 GB 0706633D0 GB 0706633 A GB0706633 A GB 0706633A GB 0706633 D0 GB0706633 D0 GB 0706633D0
Authority
GB
United Kingdom
Prior art keywords
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0706633.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Priority to GBGB0706633.5A priority Critical patent/GB0706633D0/en
Publication of GB0706633D0 publication Critical patent/GB0706633D0/en
Priority to PCT/GB2008/001189 priority patent/WO2008122779A1/en
Priority to EP08718990A priority patent/EP2139486A1/en
Priority to JP2010501589A priority patent/JP5514099B2/ja
Priority to CN2008800188649A priority patent/CN101678029B/zh
Priority to US12/573,358 priority patent/US9173938B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0706633.5A 2007-04-04 2007-04-04 Combination Ceased GB0706633D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0706633.5A GB0706633D0 (en) 2007-04-04 2007-04-04 Combination
PCT/GB2008/001189 WO2008122779A1 (en) 2007-04-04 2008-04-02 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders
EP08718990A EP2139486A1 (en) 2007-04-04 2008-04-02 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders
JP2010501589A JP5514099B2 (ja) 2007-04-04 2008-04-02 プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用
CN2008800188649A CN101678029B (zh) 2007-04-04 2008-04-02 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
US12/573,358 US9173938B2 (en) 2007-04-04 2009-10-05 Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0706633.5A GB0706633D0 (en) 2007-04-04 2007-04-04 Combination

Publications (1)

Publication Number Publication Date
GB0706633D0 true GB0706633D0 (en) 2007-05-16

Family

ID=38090894

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0706633.5A Ceased GB0706633D0 (en) 2007-04-04 2007-04-04 Combination

Country Status (6)

Country Link
US (1) US9173938B2 (enExample)
EP (1) EP2139486A1 (enExample)
JP (1) JP5514099B2 (enExample)
CN (1) CN101678029B (enExample)
GB (1) GB0706633D0 (enExample)
WO (1) WO2008122779A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
WO2010104923A1 (en) * 2009-03-11 2010-09-16 Research Development Foundation Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
KR101806323B1 (ko) * 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
ES2517367T3 (es) * 2009-12-11 2014-11-03 Niiki Pharma Inc. Procedimiento de tratamiento de cáncer pancreático
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
AU2011293315A1 (en) 2010-08-26 2013-03-14 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
TW202502325A (zh) 2013-07-12 2025-01-16 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
RU2752729C2 (ru) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP7083497B2 (ja) * 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
WO2017037292A1 (en) * 2015-09-04 2017-03-09 Aslan Pharmaceuticals Pte Limited Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10132797B2 (en) 2016-12-19 2018-11-20 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP6899504B2 (ja) * 2017-01-10 2021-07-07 ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法
EP4036583A1 (en) * 2017-08-11 2022-08-03 Board of Regents, The University of Texas System Targeting kinases for the treatment of cancer metastasis
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US20210015819A1 (en) * 2018-03-13 2021-01-21 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
JP2021525244A (ja) * 2018-05-23 2021-09-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
GB202000901D0 (en) * 2020-01-22 2020-03-04 Cyclacel Ltd Process
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
JP2006508184A (ja) 2002-11-06 2006-03-09 サイクラセル・リミテッド Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
EP2258700A1 (en) * 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
CN101678029A (zh) 2010-03-24
JP2010523536A (ja) 2010-07-15
US20100143350A1 (en) 2010-06-10
US9173938B2 (en) 2015-11-03
EP2139486A1 (en) 2010-01-06
JP5514099B2 (ja) 2014-06-04
WO2008122779A1 (en) 2008-10-16
CN101678029B (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
ZA201002568B (en) Herbicide-safener combination
GB0706633D0 (en) Combination
DE602008005470D1 (en) Imidazopyridinone
AP2010005314A0 (en) Nanodispersian
GB0701437D0 (en) Electro-chlorinator
ZA201002562B (en) Combination thepary
GB0700595D0 (en) Holecutter
DE602008004135D1 (en) Triphenylmethan- und xanthenpigmente
GB0701606D0 (en) Adjustachair
AU3613P (en) LS005A01 Leucospermum cuneiforme
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3646P (en) TAS300 Dianella tasmanica
AU3606P (en) Jaywick xTriticosecale
AU3702P (en) DarwinGold Dianella ensifolia
AU3952P (en) FLOCHRDEF Chrysocephalum apiculatum
AU3642P (en) TAS100 Dianella tasmanica
GB0707145D0 (en) Combination therapy - 793
HU0700365D0 (en) Combination
GB0700725D0 (en) Benedicta
AU320545S (en) Multi-opener
GB0700234D0 (en) Mobi-hold
GB0700193D0 (en) Plug-guard
GB0700085D0 (en) Multi-cleanser
GB0700292D0 (en) Cpmpounds
GB0700298D0 (en) Pramstand

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)